Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer

BackgroundOur study aimed to evaluate the safety and immunogenicity of the third (booster) dose of the COVID-19 vaccine for patients with endocrine-related cancers.MethodsThis observational study involved 94 breast cancer patients, 92 thyroid cancer patients, and 123 healthy individuals who had rece...

Full description

Bibliographic Details
Main Authors: Shanshan Han, Yuping Yang, Tingrui Wang, Rui Song, Daixing Hu, Mingli Peng, Zijing Lin, Qin Deng, Hong Ren, Jia Ming
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Public Health
Subjects:
SARS-CoV-2
COVID-19
vaccine
immunogenicity
endocrine-related cancer
breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2023.1086872/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2023.1086872/full

Similar Items